Icis
Clinical Trials Overview
1 trials found
About Icis
ICIs are used for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after progression on fluoropyrimidine, oxaliplatin and irinotecan; they have shown efficacy in patients with MSI-H/dMMR tumors but not typically in those with microsatellite stable (MSS) CRC.
Category
Other Medications
Brand Name
** Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab)
**
Mechanism
ICIs, such as pembrolizumab and nivolumab, block the PD-1 receptor on T-cells, enhancing their ability to recognize and attack cancer cells; ipilimumab targets CTLA-4, another immune checkpoint, thereby activating a broader T-cell response.
1
Total Trials
0
Recruiting
1
Active
0
Completed
600
Total Enrollment
1
Countries
NCT04584008
Not Applicable
Active
600 patients
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and complex, to screen pote...
China